世界の腎疾患治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Renal Diseases Drug Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4812
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、106ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、腎疾患治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（慢性腎臓病（CKD）薬、末期腎臓病（ESRD）薬）、用途別市場規模（病院、専門クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・腎疾患治療薬の市場動向
・企業の競争状況、市場シェア
・腎疾患治療薬の種類別市場規模と予測2016-2027（慢性腎臓病（CKD）薬、末期腎臓病（ESRD）薬）
・腎疾患治療薬の用途別市場規模と予測2016-2027（病院、専門クリニック、その他）
・腎疾患治療薬の北米市場規模2016-2027（アメリカ、カナダ）
・腎疾患治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・腎疾患治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・腎疾患治療薬の中南米市場規模2016-2027（メキシコ、ブラジル）
・腎疾患治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Pfizer、Amgen、Roche、GlaxoSmithKline (GSK)、Allergan、AbbVie、Kissei Pharmaceutical、AstraZeneca、FibroGen、Sanofi、Teva Pharmaceutical Industries、Johnson & Johnson、Keryx Biopharmaceuticals）
・結論

Kidney disease commonly referred to as kidney disease or kidney disease, mainly manifested as abnormal urine volume, urination abnormalities, lumbago.Kidney disease drugs include blood pressure drugs, anti-hyperlipidemia drugs, erythropoietics (ESA), diuretics and so on.

Market Analysis and Insights: Global Renal Diseases Drug Market
The global Renal Diseases Drug market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Renal Diseases Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Renal Diseases Drug market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Renal Diseases Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Renal Diseases Drug market.

Global Renal Diseases Drug Scope and Market Size
Renal Diseases Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Renal Diseases Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Chronic Kidney Disease (CKD) Drugs
End-Stage Kidney Disease (ESRD) Drugs

Segment by Application
Hospitals
Specialty Clinics
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
Amgen
Roche
GlaxoSmithKline (GSK)
Allergan
AbbVie
Kissei Pharmaceutical
AstraZeneca
FibroGen
Sanofi
Teva Pharmaceutical Industries
Johnson & Johnson
Keryx Biopharmaceuticals

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Renal Diseases Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Chronic Kidney Disease (CKD) Drugs
1.2.3 End-Stage Kidney Disease (ESRD) Drugs
1.3 Market by Application
1.3.1 Global Renal Diseases Drug Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Renal Diseases Drug Market Perspective (2016-2027)
2.2 Renal Diseases Drug Growth Trends by Regions
2.2.1 Renal Diseases Drug Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Renal Diseases Drug Historic Market Share by Regions (2016-2021)
2.2.3 Renal Diseases Drug Forecasted Market Size by Regions (2022-2027)
2.3 Renal Diseases Drug Industry Dynamic
2.3.1 Renal Diseases Drug Market Trends
2.3.2 Renal Diseases Drug Market Drivers
2.3.3 Renal Diseases Drug Market Challenges
2.3.4 Renal Diseases Drug Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Renal Diseases Drug Players by Revenue
3.1.1 Global Top Renal Diseases Drug Players by Revenue (2016-2021)
3.1.2 Global Renal Diseases Drug Revenue Market Share by Players (2016-2021)
3.2 Global Renal Diseases Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Renal Diseases Drug Revenue
3.4 Global Renal Diseases Drug Market Concentration Ratio
3.4.1 Global Renal Diseases Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Renal Diseases Drug Revenue in 2020
3.5 Renal Diseases Drug Key Players Head office and Area Served
3.6 Key Players Renal Diseases Drug Product Solution and Service
3.7 Date of Enter into Renal Diseases Drug Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Renal Diseases Drug Breakdown Data by Type
4.1 Global Renal Diseases Drug Historic Market Size by Type (2016-2021)
4.2 Global Renal Diseases Drug Forecasted Market Size by Type (2022-2027)

5 Renal Diseases Drug Breakdown Data by Application
5.1 Global Renal Diseases Drug Historic Market Size by Application (2016-2021)
5.2 Global Renal Diseases Drug Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Renal Diseases Drug Market Size (2016-2027)
6.2 North America Renal Diseases Drug Market Size by Type
6.2.1 North America Renal Diseases Drug Market Size by Type (2016-2021)
6.2.2 North America Renal Diseases Drug Market Size by Type (2022-2027)
6.2.3 North America Renal Diseases Drug Market Size by Type (2016-2027)
6.3 North America Renal Diseases Drug Market Size by Application
6.3.1 North America Renal Diseases Drug Market Size by Application (2016-2021)
6.3.2 North America Renal Diseases Drug Market Size by Application (2022-2027)
6.3.3 North America Renal Diseases Drug Market Size by Application (2016-2027)
6.4 North America Renal Diseases Drug Market Size by Country
6.4.1 North America Renal Diseases Drug Market Size by Country (2016-2021)
6.4.2 North America Renal Diseases Drug Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Renal Diseases Drug Market Size (2016-2027)
7.2 Europe Renal Diseases Drug Market Size by Type
7.2.1 Europe Renal Diseases Drug Market Size by Type (2016-2021)
7.2.2 Europe Renal Diseases Drug Market Size by Type (2022-2027)
7.2.3 Europe Renal Diseases Drug Market Size by Type (2016-2027)
7.3 Europe Renal Diseases Drug Market Size by Application
7.3.1 Europe Renal Diseases Drug Market Size by Application (2016-2021)
7.3.2 Europe Renal Diseases Drug Market Size by Application (2022-2027)
7.3.3 Europe Renal Diseases Drug Market Size by Application (2016-2027)
7.4 Europe Renal Diseases Drug Market Size by Country
7.4.1 Europe Renal Diseases Drug Market Size by Country (2016-2021)
7.4.2 Europe Renal Diseases Drug Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Renal Diseases Drug Market Size (2016-2027)
8.2 Asia-Pacific Renal Diseases Drug Market Size by Type
8.2.1 Asia-Pacific Renal Diseases Drug Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Renal Diseases Drug Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Renal Diseases Drug Market Size by Type (2016-2027)
8.3 Asia-Pacific Renal Diseases Drug Market Size by Application
8.3.1 Asia-Pacific Renal Diseases Drug Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Renal Diseases Drug Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Renal Diseases Drug Market Size by Application (2016-2027)
8.4 Asia-Pacific Renal Diseases Drug Market Size by Region
8.4.1 Asia-Pacific Renal Diseases Drug Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Renal Diseases Drug Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Renal Diseases Drug Market Size (2016-2027)
9.2 Latin America Renal Diseases Drug Market Size by Type
9.2.1 Latin America Renal Diseases Drug Market Size by Type (2016-2021)
9.2.2 Latin America Renal Diseases Drug Market Size by Type (2022-2027)
9.2.3 Latin America Renal Diseases Drug Market Size by Type (2016-2027)
9.3 Latin America Renal Diseases Drug Market Size by Application
9.3.1 Latin America Renal Diseases Drug Market Size by Application (2016-2021)
9.3.2 Latin America Renal Diseases Drug Market Size by Application (2022-2027)
9.3.3 Latin America Renal Diseases Drug Market Size by Application (2016-2027)
9.4 Latin America Renal Diseases Drug Market Size by Country
9.4.1 Latin America Renal Diseases Drug Market Size by Country (2016-2021)
9.4.2 Latin America Renal Diseases Drug Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Renal Diseases Drug Market Size (2016-2027)
10.2 Middle East & Africa Renal Diseases Drug Market Size by Type
10.2.1 Middle East & Africa Renal Diseases Drug Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Renal Diseases Drug Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Renal Diseases Drug Market Size by Type (2016-2027)
10.3 Middle East & Africa Renal Diseases Drug Market Size by Application
10.3.1 Middle East & Africa Renal Diseases Drug Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Renal Diseases Drug Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Renal Diseases Drug Market Size by Application (2016-2027)
10.4 Middle East & Africa Renal Diseases Drug Market Size by Country
10.4.1 Middle East & Africa Renal Diseases Drug Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Renal Diseases Drug Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Renal Diseases Drug Introduction
11.1.4 Pfizer Revenue in Renal Diseases Drug Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Renal Diseases Drug Introduction
11.2.4 Amgen Revenue in Renal Diseases Drug Business (2016-2021)
11.2.5 Amgen Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Renal Diseases Drug Introduction
11.3.4 Roche Revenue in Renal Diseases Drug Business (2016-2021)
11.3.5 Roche Recent Development
11.4 GlaxoSmithKline (GSK)
11.4.1 GlaxoSmithKline (GSK) Company Details
11.4.2 GlaxoSmithKline (GSK) Business Overview
11.4.3 GlaxoSmithKline (GSK) Renal Diseases Drug Introduction
11.4.4 GlaxoSmithKline (GSK) Revenue in Renal Diseases Drug Business (2016-2021)
11.4.5 GlaxoSmithKline (GSK) Recent Development
11.5 Allergan
11.5.1 Allergan Company Details
11.5.2 Allergan Business Overview
11.5.3 Allergan Renal Diseases Drug Introduction
11.5.4 Allergan Revenue in Renal Diseases Drug Business (2016-2021)
11.5.5 Allergan Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Details
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Renal Diseases Drug Introduction
11.6.4 AbbVie Revenue in Renal Diseases Drug Business (2016-2021)
11.6.5 AbbVie Recent Development
11.7 Kissei Pharmaceutical
11.7.1 Kissei Pharmaceutical Company Details
11.7.2 Kissei Pharmaceutical Business Overview
11.7.3 Kissei Pharmaceutical Renal Diseases Drug Introduction
11.7.4 Kissei Pharmaceutical Revenue in Renal Diseases Drug Business (2016-2021)
11.7.5 Kissei Pharmaceutical Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Renal Diseases Drug Introduction
11.8.4 AstraZeneca Revenue in Renal Diseases Drug Business (2016-2021)
11.8.5 AstraZeneca Recent Development
11.9 FibroGen
11.9.1 FibroGen Company Details
11.9.2 FibroGen Business Overview
11.9.3 FibroGen Renal Diseases Drug Introduction
11.9.4 FibroGen Revenue in Renal Diseases Drug Business (2016-2021)
11.9.5 FibroGen Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Details
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Renal Diseases Drug Introduction
11.10.4 Sanofi Revenue in Renal Diseases Drug Business (2016-2021)
11.10.5 Sanofi Recent Development
11.11 Teva Pharmaceutical Industries
11.11.1 Teva Pharmaceutical Industries Company Details
11.11.2 Teva Pharmaceutical Industries Business Overview
11.11.3 Teva Pharmaceutical Industries Renal Diseases Drug Introduction
11.11.4 Teva Pharmaceutical Industries Revenue in Renal Diseases Drug Business (2016-2021)
11.11.5 Teva Pharmaceutical Industries Recent Development
11.12 Johnson & Johnson
11.12.1 Johnson & Johnson Company Details
11.12.2 Johnson & Johnson Business Overview
11.12.3 Johnson & Johnson Renal Diseases Drug Introduction
11.12.4 Johnson & Johnson Revenue in Renal Diseases Drug Business (2016-2021)
11.12.5 Johnson & Johnson Recent Development
11.13 Keryx Biopharmaceuticals
11.13.1 Keryx Biopharmaceuticals Company Details
11.13.2 Keryx Biopharmaceuticals Business Overview
11.13.3 Keryx Biopharmaceuticals Renal Diseases Drug Introduction
11.13.4 Keryx Biopharmaceuticals Revenue in Renal Diseases Drug Business (2016-2021)
11.13.5 Keryx Biopharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Renal Diseases Drug Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Chronic Kidney Disease (CKD) Drugs
Table 3. Key Players of End-Stage Kidney Disease (ESRD) Drugs
Table 4. Global Renal Diseases Drug Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Renal Diseases Drug Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Renal Diseases Drug Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Renal Diseases Drug Market Share by Regions (2016-2021)
Table 8. Global Renal Diseases Drug Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Renal Diseases Drug Market Share by Regions (2022-2027)
Table 10. Renal Diseases Drug Market Trends
Table 11. Renal Diseases Drug Market Drivers
Table 12. Renal Diseases Drug Market Challenges
Table 13. Renal Diseases Drug Market Restraints
Table 14. Global Renal Diseases Drug Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Renal Diseases Drug Market Share by Players (2016-2021)
Table 16. Global Top Renal Diseases Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Renal Diseases Drug as of 2020)
Table 17. Ranking of Global Top Renal Diseases Drug Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Renal Diseases Drug Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Renal Diseases Drug Product Solution and Service
Table 21. Date of Enter into Renal Diseases Drug Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Renal Diseases Drug Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Renal Diseases Drug Revenue Market Share by Type (2016-2021)
Table 25. Global Renal Diseases Drug Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Renal Diseases Drug Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Renal Diseases Drug Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Renal Diseases Drug Revenue Market Share by Application (2016-2021)
Table 29. Global Renal Diseases Drug Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Renal Diseases Drug Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Renal Diseases Drug Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Renal Diseases Drug Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Renal Diseases Drug Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Renal Diseases Drug Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Renal Diseases Drug Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Renal Diseases Drug Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Renal Diseases Drug Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Renal Diseases Drug Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Renal Diseases Drug Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Renal Diseases Drug Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Renal Diseases Drug Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Renal Diseases Drug Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Renal Diseases Drug Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Renal Diseases Drug Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Renal Diseases Drug Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Renal Diseases Drug Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Renal Diseases Drug Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Renal Diseases Drug Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Renal Diseases Drug Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Renal Diseases Drug Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Renal Diseases Drug Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Renal Diseases Drug Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Renal Diseases Drug Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Renal Diseases Drug Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Renal Diseases Drug Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Renal Diseases Drug Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Renal Diseases Drug Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Renal Diseases Drug Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Renal Diseases Drug Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Renal Diseases Drug Market Size by Country (2022-2027) & (US$ Million)
Table 61. Pfizer Company Details
Table 62. Pfizer Business Overview
Table 63. Pfizer Renal Diseases Drug Product
Table 64. Pfizer Revenue in Renal Diseases Drug Business (2016-2021) & (US$ Million)
Table 65. Pfizer Recent Development
Table 66. Amgen Company Details
Table 67. Amgen Business Overview
Table 68. Amgen Renal Diseases Drug Product
Table 69. Amgen Revenue in Renal Diseases Drug Business (2016-2021) & (US$ Million)
Table 70. Amgen Recent Development
Table 71. Roche Company Details
Table 72. Roche Business Overview
Table 73. Roche Renal Diseases Drug Product
Table 74. Roche Revenue in Renal Diseases Drug Business (2016-2021) & (US$ Million)
Table 75. Roche Recent Development
Table 76. GlaxoSmithKline (GSK) Company Details
Table 77. GlaxoSmithKline (GSK) Business Overview
Table 78. GlaxoSmithKline (GSK) Renal Diseases Drug Product
Table 79. GlaxoSmithKline (GSK) Revenue in Renal Diseases Drug Business (2016-2021) & (US$ Million)
Table 80. GlaxoSmithKline (GSK) Recent Development
Table 81. Allergan Company Details
Table 82. Allergan Business Overview
Table 83. Allergan Renal Diseases Drug Product
Table 84. Allergan Revenue in Renal Diseases Drug Business (2016-2021) & (US$ Million)
Table 85. Allergan Recent Development
Table 86. AbbVie Company Details
Table 87. AbbVie Business Overview
Table 88. AbbVie Renal Diseases Drug Product
Table 89. AbbVie Revenue in Renal Diseases Drug Business (2016-2021) & (US$ Million)
Table 90. AbbVie Recent Development
Table 91. Kissei Pharmaceutical Company Details
Table 92. Kissei Pharmaceutical Business Overview
Table 93. Kissei Pharmaceutical Renal Diseases Drug Product
Table 94. Kissei Pharmaceutical Revenue in Renal Diseases Drug Business (2016-2021) & (US$ Million)
Table 95. Kissei Pharmaceutical Recent Development
Table 96. AstraZeneca Company Details
Table 97. AstraZeneca Business Overview
Table 98. AstraZeneca Revenue in Renal Diseases Drug Business (2016-2021) & (US$ Million)
Table 99. AstraZeneca Recent Development
Table 100. FibroGen Company Details
Table 101. FibroGen Business Overview
Table 102. FibroGen Renal Diseases Drug Product
Table 103. FibroGen Revenue in Renal Diseases Drug Business (2016-2021) & (US$ Million)
Table 104. FibroGen Recent Development
Table 105. Sanofi Company Details
Table 106. Sanofi Business Overview
Table 107. Sanofi Renal Diseases Drug Product
Table 108. Sanofi Revenue in Renal Diseases Drug Business (2016-2021) & (US$ Million)
Table 109. Sanofi Recent Development
Table 110. Teva Pharmaceutical Industries Company Details
Table 111. Teva Pharmaceutical Industries Business Overview
Table 112. Teva Pharmaceutical Industries Renal Diseases Drug Product
Table 113. Teva Pharmaceutical Industries Revenue in Renal Diseases Drug Business (2016-2021) & (US$ Million)
Table 114. Teva Pharmaceutical Industries Recent Development
Table 115. Johnson & Johnson Company Details
Table 116. Johnson & Johnson Business Overview
Table 117. Johnson & Johnson Renal Diseases Drug Product
Table 118. Johnson & Johnson Revenue in Renal Diseases Drug Business (2016-2021) & (US$ Million)
Table 119. Johnson & Johnson Recent Development
Table 120. Keryx Biopharmaceuticals Company Details
Table 121. Keryx Biopharmaceuticals Business Overview
Table 122. Keryx Biopharmaceuticals Renal Diseases Drug Product
Table 123. Keryx Biopharmaceuticals Revenue in Renal Diseases Drug Business (2016-2021) & (US$ Million)
Table 124. Keryx Biopharmaceuticals Recent Development
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Renal Diseases Drug Market Share by Type: 2020 VS 2027
Figure 2. Chronic Kidney Disease (CKD) Drugs Features
Figure 3. End-Stage Kidney Disease (ESRD) Drugs Features
Figure 4. Global Renal Diseases Drug Market Share by Application: 2020 VS 2027
Figure 5. Hospitals Case Studies
Figure 6. Specialty Clinics Case Studies
Figure 7. Other Case Studies
Figure 8. Renal Diseases Drug Report Years Considered
Figure 9. Global Renal Diseases Drug Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Renal Diseases Drug Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Renal Diseases Drug Market Share by Regions: 2020 VS 2027
Figure 12. Global Renal Diseases Drug Market Share by Regions (2022-2027)
Figure 13. Global Renal Diseases Drug Market Share by Players in 2020
Figure 14. Global Top Renal Diseases Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Renal Diseases Drug as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Renal Diseases Drug Revenue in 2020
Figure 16. Global Renal Diseases Drug Revenue Market Share by Type (2016-2021)
Figure 17. Global Renal Diseases Drug Revenue Market Share by Type (2022-2027)
Figure 18. North America Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Renal Diseases Drug Market Share by Type (2016-2027)
Figure 20. North America Renal Diseases Drug Market Share by Application (2016-2027)
Figure 21. North America Renal Diseases Drug Market Share by Country (2016-2027)
Figure 22. United States Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Renal Diseases Drug Market Share by Type (2016-2027)
Figure 26. Europe Renal Diseases Drug Market Share by Application (2016-2027)
Figure 27. Europe Renal Diseases Drug Market Share by Country (2016-2027)
Figure 28. Germany Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Renal Diseases Drug Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Renal Diseases Drug Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Renal Diseases Drug Market Share by Region (2016-2027)
Figure 38. China Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Renal Diseases Drug Market Share by Type (2016-2027)
Figure 46. Latin America Renal Diseases Drug Market Share by Application (2016-2027)
Figure 47. Latin America Renal Diseases Drug Market Share by Country (2016-2027)
Figure 48. Mexico Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Renal Diseases Drug Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Renal Diseases Drug Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Renal Diseases Drug Market Share by Country (2016-2027)
Figure 54. Turkey Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Renal Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Pfizer Revenue Growth Rate in Renal Diseases Drug Business (2016-2021)
Figure 58. Amgen Revenue Growth Rate in Renal Diseases Drug Business (2016-2021)
Figure 59. Roche Revenue Growth Rate in Renal Diseases Drug Business (2016-2021)
Figure 60. GlaxoSmithKline (GSK) Revenue Growth Rate in Renal Diseases Drug Business (2016-2021)
Figure 61. Allergan Revenue Growth Rate in Renal Diseases Drug Business (2016-2021)
Figure 62. AbbVie Revenue Growth Rate in Renal Diseases Drug Business (2016-2021)
Figure 63. Kissei Pharmaceutical Revenue Growth Rate in Renal Diseases Drug Business (2016-2021)
Figure 64. AstraZeneca Revenue Growth Rate in Renal Diseases Drug Business (2016-2021)
Figure 65. FibroGen Revenue Growth Rate in Renal Diseases Drug Business (2016-2021)
Figure 66. Sanofi Revenue Growth Rate in Renal Diseases Drug Business (2016-2021)
Figure 67. Teva Pharmaceutical Industries Revenue Growth Rate in Renal Diseases Drug Business (2016-2021)
Figure 68. Johnson & Johnson Revenue Growth Rate in Renal Diseases Drug Business (2016-2021)
Figure 69. Keryx Biopharmaceuticals Revenue Growth Rate in Renal Diseases Drug Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

以下、関連資料のご紹介

世界の腎臓バイオマーカー市場規模・現状・予測（2021年-2027年）

Global Renal Biomarker Market Size, Status and Forecast 2021-2027
QFJ1-4807 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、腎臓バイオマーカーの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（機能性バイオマーカー、アップレギュレート化タンパク質、その他）、用途別市場規模（病院、診断研究所、その他）、主要地域別市場規模（北米、...

世界のスニチニブ薬市場規模・現状・予測（2021年-2027年）

Global Sunitinib Drug Market Size, Status and Forecast 2021-2027
QFJ1-6026 2021年6月 89Pages
QYResearch社発行の本調査レポートでは、スニチニブ薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（12.5mgカプセル、25mgカプセル、37.5mgカプセル、50mgカプセル）、用途別市場規模（腎臓がん、GIST、pNET）、主要地域別...

世界の末期腎疾患治療市場規模・現状・予測（2021年-2027年）

Global End Stage Renal Disease Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4184 2021年6月 108Pages
QYResearch社発行の本調査レポートでは、末期腎疾患治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（移植、透析）、用途別市場規模（公立病院、私立病院）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア...

世界の腎臓癌＆腎細胞癌（RCC）治療薬市場規模・現状・予測（2021年-2027年）

Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, Status and Forecast 2021-2027
QFJ1-5819 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、腎臓癌＆腎細胞癌（RCC）治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アフィニトール（エベロリムス）、アバスチン（ベバシズマブ）、カボメティ（カボザンチニブ）、インリタ（アキシチニブ）、ネク...

世界のアンブリセンタン薬市場規模・現状・予測（2021年-2027年）

Global Ambrisentan Drug Market Size, Status and Forecast 2021-2027
QFJ1-5574 2021年6月 87Pages
QYResearch社発行の本調査レポートでは、アンブリセンタン薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（5mg錠、10mg錠）、用途別市場規模（病院、薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南...

世界の腎細胞がん治療市場規模・現状・予測（2021年-2027年）

Global Renal Cell Cancer Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5989 2021年6月 118Pages
QYResearch社発行の本調査レポートでは、腎細胞がん治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（モノクローナル抗体、mTOR阻害剤、キナーゼ阻害剤、その他）、用途別市場規模（病院、薬局、その他）、主要地域別市場規模（北米、アメリカ、欧...

世界のスマートピルドラッグデリバリー市場規模・現状・予測（2021年-2027年）

Global Smart Pills Drug Delivery Market Size, Status and Forecast 2021-2027
QFJ1-4879 2021年6月 108Pages
QYResearch社発行の本調査レポートでは、スマートピルドラッグデリバリーの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（胃、食道、小腸、大腸）、用途別市場規模（食道疾患、小腸疾患、結腸疾患、その他）、主要地域別市場規模（北米、アメリカ、欧州、...

世界の向精神薬市場規模・現状・予測（2021年-2027年）

Global Psychotropic Drug Market Size, Status and Forecast 2021-2027
QFJ1-4785 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、向精神薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（鎮痛薬、麻酔薬、催眠薬、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、...

世界のパルボシクリブ薬市場規模・現状・予測（2021年-2027年）

Global Palbociclib Drug Market Size, Status and Forecast 2021-2027
QFJ1-5925 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、パルボシクリブ薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（錠剤タイプパルボシクリブ薬、カプセルタイプパルボシクリブ薬）、用途別市場規模（病院、診断センター、研究所）、主要地域別市場規模（北米、ア...

世界のノイラミニダーゼ阻害薬市場規模・現状・予測（2021年-2027年）

Global Neuraminidase Inhibitors Drug Market Size, Status and Forecast 2021-2027
QFJ1-5878 2021年6月 86Pages
QYResearch社発行の本調査レポートでは、ノイラミニダーゼ阻害薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（オセルタミビル、ザナミビル、ペラミビル、ラニナミビル）、用途別市場規模（病院薬局、小売薬局、オンライン薬局、その他）、主要地域別市...

世界の腎臓癌＆腎細胞癌（RCC）治療薬市場規模・現状・予測（2021年-2027年） Kidney cancer/ renal cell carcinoma (RCC) is among ten most commonly observed cancer these days. It is sixth common cancer observed in men and it is the tenth most common cause of cancer for women. Market Analysis and Insights: Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market The glo…
世界の末期腎疾患治療市場規模・現状・予測（2021年-2027年） Any condition that causes reduced kidney function leads to chronic kidney disease (CKD), which may develop over a period and lead to end stage renal disease (ESRD), where kidney can no longer function on their own. It is also termed as kidney or renal failure. Factors contributing to the formation o…
末期腎不全（ESRD）薬のグローバル市場調査 2019年 The global End-Stage Renal Disease (ESRD) Drugs market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on End-Stage Renal Disease (ESRD) Drugs volume and value at global level, regional level and company leve…
世界の多発性嚢胞腎治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Polycystic Kidney Disease Treatment Drugs Market The global Polycystic Kidney Disease Treatment Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in anal…
世界のAPOL1関与腎臓病市場規模・現状・予測（2021年-2027年） APOL1 gene is a member of APOL gene family, which plays an important role in innate immunity, which is our body’s built-in defense system to fight threats. Some variations in APOL1 gene cause damage to parts within the kidney. Damage to parts that filter blood can lead to severe kidney disease or ul…